A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

NCT05348785 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

650

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: BIIB122
DRUG: BIIB122-Matching Placebo

Sponsor

Biogen

Collaborators

[object Object]